Wolf J, Mazieres J, Oh IJ, et al. Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated alk+ non-small-cell lung cancer (NSCLC). ESMO 2017, abstract 1299O_PR.,Gadgeel S, Peters S, Mok T, et al. Alectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study. ESMO1298O_PR.
Gepersonaliseerde geneeskunde in de oncologie: een sprookje of realiteit?
aug 2020 | Borstkanker, Bot en wekedelentumoren, Chirurgie, Dermato-oncologie, Gynaecologische oncologie, Hoofd-halsoncologie, Immuuntherapie, Longoncologie, Maag-darm-leveroncologie, Mesothelioom, Uro-oncologie